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Deconstructing Stent Polymers*
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Ocala, Florida
Jacques Derrida delivered the lecture, “Structure, Sign, and
Play in the Discourse of the Human Sciences,” at Johns
Hopkins on October 21, 1966, and launched the philo-
sophical movement known as deconstruction (1). Decon-
struction, which diverges from the traditional philosophical
search for universal truths, breaks down the hierarchy of
privileged concepts that exists in word pairs called binaries.See page 299A binary is a set of related terms such as rationality/emotion,
essence/existence, speech/writing, ordin the setting of
sponsored trialsdcase/control, in which the ﬁrst term is
perceived to be favored over the second. Deconstruction,
which questions the existence of privileged concepts and
replaces the structure of binaries with “a full free play of
meaning,” comprises a nearly incomprehensible approach for
philosophical discourse (2) and probably irrelevant process
for most clinical investigation but might cast a fresh view of
the evidence for using bioabsorbable polymers (BPs) in favor
of durable polymers (DPs), or no polymer at all, on coronary
stents.
Current study. In a study reported in this issue of the
Journal, Palmerini et al. (3) describe a Bayesian network
meta-analysis of 89 clinical trials that compares the relative
safety of bioabsorbable-polymer biolimus-eluting stents
(BP-BES), durable-polymer drug-eluting stents (DP-DES),
and bare-metal stents (BMS).
The analytical methods for this analysis are complex, but
the main results are straightforward. Although BP-BES,
DP-DES, and BMS are equivalent for most endpoints,
several differences are observed. First, BP-BES have higher
rates of 1-year deﬁnite stent thrombosis (ST) (posterior
median odds ratio [OR]: 2.44, 95% Bayesian credible
intervals [95% BCI]: 1.30 to 4.76) and higher long-term
deﬁnite ST (OR: 1.92, 95% BCI: 1.02 to 3.45) than
durable-polymer cobalt-chromium everolimus-eluting stents
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contents of this paper to disclose.1-year myocardial infarction (OR: 0.68, 95% BCI: 0.52 to
0.88) and lower long-term deﬁnite or probable ST (OR:
0.60, 95% BCI: 0.40 to 0.89) than BMS. Lastly, BP-BES
have lower rates of long-term myocardial infarction (OR:
0.73, 95% BCI: 0.59 to 0.99) and lower deﬁnite or probable
ST (OR: 0.52, 95% BCI: 0.31 to 0.81) than DP-PES. The
robust analysis thus creates the following hierarchy, which
lists stents from most to least preferred:
DP-CoCr-EES > BP-BES > BMS
or first-generation DP-PES
Bayesian perspective. The Bayesian meta-analysis, which
requires no adjustments for multiple simultaneous compari-
sons, generates credible intervals (BCIs) that differ from
traditional conﬁdence intervals (CIs) in several ways (4). The
traditional approach deﬁnes probability as a limit as the
number of observations hypothetically approaches inﬁnity and
thus measures a frequency. If a large number of traditional
frequentist 95% CIs could be generated, 95% of them should
contain the trueOR, but the actual probability that a particular
CI contains the true OR cannot be stated (4). In other words,
the probability that a given 95% CI contains the true OR is
either 0 or 1. It either does or it does not.
The Bayesian meta-analysis generates a 95% BCI that has
a 95% probability of containing the true OR, a characteristic
that is commonly but erroneously attributed to the tradi-
tional frequentist CI (4). For example, the 95% BCI of 1.30
to 4.76 for 1-year ST after BP-BES compared with DP-
CoCr-EES has a 95% chance of containing the true OR,
conﬁrming that the higher rate of ST after BP-BES is
believable and virtually certain. The possibility that the 2
stents have the same risk of ST is extremely small.
According to the deﬁnition of the 95% BCI, there is only
a 2.5% chance that the odds of ST after BP-BES compared
with DP-CoCr-EES is less than the lower boundary of the
credible interval. The overall results of the network meta-
analysis suggest that the risk of ST is related to stent
design, on the basis of the assumption that patients in the
randomized stent trials were sampled from similar
populations.
Polymers. The Biomatrix BP-BES and Nobori stents
(Terumo Corporation, Tokyo, Japan) have a BP comprising
polyglycolic acid/polylactic acid (PGLA). The Promus and
Xience stents (Boston Scientiﬁc, Natick, Massachusetts) use
a DP made of a ﬂuorinated polymer consisting of poly-
vinylidene ﬂuoride (PVDF) and hexaﬂuoropropylene (HFP)
monomers. The Endeavor stents (Medtronic, Minneapolis,
Minnesota) have a DP made of phosphorylcholine (PC),
and the Endeavor Resolute stent (Medtronic) has a DP
made of the proprietary BioLinx polymer, consisting of
a hydrophobic C10 component, a hydrophilic polyvinyl-
pyrrolidinone and a C19 composite component.
Inﬂammation. The development of BPs was based on the
premise that they cause less vascular inﬂammation and ﬁbrin
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309deposition than DPs, but different polymer types might
actually cause similar vascular responses. van der Giessen
et al. (5) described the reaction of porcine coronary arteries to
5 different BPs, including PGLA, polycaprolactone, poly-
hydroxybutyrate valerate, polyorthoester, and polyethylene-
oxide/polybutylene terephthalate and 3 DPs including
polyurethane, silicone, and polyethylene terephthalate. The
biodegradable polycaprolactone, polyhydroxybutyrate valerate,
and polyorthoester and the nonbiodegradable polyurethane
and silicone evoked extensive inﬂammatory responses and
ﬁbrocellular proliferation. Less but still severe responses were
observed for the biodegradable PGLA and polyethyleneoxide/
polybutylene terephthalate and for the nonbiodegradable
polyethylene terephthalate. The investigators concluded
that all polymers have the potential to cause vascular inﬂam-
mation (5).
Thromboresistance. Several studies suggest that the
surface potential, wettability, and smoothness of certain
polymers might confer thromboresistance. One study
suggests that PVDF-HEP and PC have equivalent throm-
boresistance (6). Several studies suggest that VDF-grafted
polymers are less likely than untreated polymers to activate
platelets (7,8). A study by Kolandaivelu et al. (9) has shown
that the risk of acute stent thrombosis in high-risk inter-
ventional settings is reduced by the presence of a ﬂuoropol-
ymer. With a Chandler loop model, the investigators have
observed that the rate of thrombosis of DP-CoCr-EES in
silico is lower than that for matched BMS and remains
insensitive to incomplete deployment. Comparing ﬂuo-
ropolymers with stent metals, Eppihimer et al. (10) have
found less platelet adhesion on the platinum chromium
(PtCr) of the fourth-generation PtCr-EES than on PVDF-
HFP polymers.
Deconstruction. The titular goal of the current study was
to compare “bioabsorbable polymer-based versus durable
polymer-based drug-eluting stents,” but the authors of the
current report (3) make no deﬁnitive conclusions about the
superiority of BPs versus DPs and “refrain from giving
recommendations about the use of a speciﬁc device.” The
investigators cannot be faulted for a cautious interpretation
of their own data, but in rejecting the possibility of a favored
polymer or device after such a thorough analysis, the
investigators present an aporeia (Greek, impasse) and, like
Derrida, invoke the philosophy of Gorgias the Sophist, who
wrote (2):
Nothing exists.
If it exists, it cannot be known.
If it can be known, it cannot be communicated.
If it can be communicated, it cannot be understood.
Denouement. The weight of evidence in the current
analysis (3) supports conclusions about polymer types and
devices. The large sample size, absence of heterogeneityacross multiple comparisons, the stability of results across
several sensitivity analyses, and consistency between direct
and indirect estimates constitute robust scientiﬁc evidence to
demonstrate that BPs do not outperform ﬂuoropolymer
DPs. The analysis in the current report (3) suggests that the
DP-CoCr-EES and their PtCr analogs are the preferred
devices for coronary stenting in current practice.
Scientiﬁc progress is incremental. Complex datasets often
require advanced methods of analysis. The Bayesian
approach of network meta-analysis allows statistical infer-
ences to be made when direct comparisons do not exist. A
“discriminating, philosophical and fearless” approach bor-
rowed from literary criticism (11) helps to translate trial
evidence into clinical practice to keep the ﬁeld moving
forward.
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